Literature DB >> 27754901

Predicting Regional Pattern of Longitudinal β-Amyloid Accumulation by Baseline PET.

Tengfei Guo1, Matthias Brendel2, Timo Grimmer3, Axel Rominger2, Igor Yakushev.   

Abstract

Knowledge about spatial and temporal patterns of β-amyloid (Aβ) accumulation is essential for understanding Alzheimer disease (AD) and for design of antiamyloid drug trials. Here, we tested whether the regional pattern of longitudinal Aβ accumulation can be predicted by baseline amyloid PET.
Methods: Baseline and 2-y follow-up 18F-florbetapir PET data from 58 patients with incipient and manifest dementia due to AD were analyzed. With the determination of how fast amyloid deposits in a given region relative to the whole-brain gray matter, a pseudotemporal accumulation rate for each region was calculated. The actual accumulation rate of 18F-florbetapir was calculated from follow-up data.
Results: Pseudotemporal measurements from baseline PET data explained 87% (P < 0.001) of the variance in longitudinal accumulation rate across 62 regions. The method accurately predicted the top 10 fast and slow accumulating regions.
Conclusion: Pseudotemporal analysis of baseline PET images is capable of predicting the regional pattern of longitudinal Aβ accumulation in AD at a group level. This approach may be useful in exploring spatial patterns of Aβ accumulation in other amyloid-associated disorders such as Lewy body disease and atypical forms of AD. In addition, the method allows identification of brain regions with a high accumulation rate of Aβ, which are of particular interest for antiamyloid clinical trials.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  Alzheimer’s disease; amyloid imaging; clinical trial; dementia; mild cognitive impairment

Mesh:

Substances:

Year:  2016        PMID: 27754901      PMCID: PMC5373505          DOI: 10.2967/jnumed.116.176115

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  30 in total

1.  Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data.

Authors:  Andrei G Vlassenko; Mark A Mintun; Chengjie Xiong; Yvette I Sheline; Alison M Goate; Tammie L S Benzinger; John C Morris
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

2.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Authors:  Nicolas Villain; Gaël Chételat; Blandine Grassiot; Pierrick Bourgeat; Gareth Jones; Kathryn A Ellis; David Ames; Ralph N Martins; Francis Eustache; Olivier Salvado; Colin L Masters; Christopher C Rowe; Victor L Villemagne
Journal:  Brain       Date:  2012-05-23       Impact factor: 13.501

3.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

4.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

5.  Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.

Authors:  Wai-Ying Wendy Yau; Dana L Tudorascu; Eric M McDade; Snezana Ikonomovic; Jeffrey A James; Davneet Minhas; Wenzhu Mowrey; Lei K Sheu; Beth E Snitz; Lisa Weissfeld; Peter J Gianaros; Howard J Aizenstein; Julie C Price; Chester A Mathis; Oscar L Lopez; William E Klunk
Journal:  Lancet Neurol       Date:  2015-06-29       Impact factor: 44.182

6.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

7.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Authors:  Henry Engler; Anton Forsberg; Ove Almkvist; Gunnar Blomquist; Emma Larsson; Irina Savitcheva; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Brain       Date:  2006-07-19       Impact factor: 13.501

8.  Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden.

Authors:  Rachel A Yotter; Jimit Doshi; Vanessa Clark; Jitka Sojkova; Yun Zhou; Dean F Wong; Luigi Ferrucci; Susan M Resnick; Christos Davatzikos
Journal:  Neurobiol Aging       Date:  2013-07-13       Impact factor: 4.673

9.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

10.  Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

Authors:  Eric R Siemers; Karen L Sundell; Christopher Carlson; Michael Case; Gopalan Sethuraman; Hong Liu-Seifert; Sherie A Dowsett; Michael J Pontecorvo; Robert A Dean; Ronald Demattos
Journal:  Alzheimers Dement       Date:  2015-08-01       Impact factor: 21.566

View more
  5 in total

1.  Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration.

Authors:  Chin Hong Tan; Luke W Bonham; Chun Chieh Fan; Elizabeth C Mormino; Leo P Sugrue; Iris J Broce; Christopher P Hess; Jennifer S Yokoyama; Gil D Rabinovici; Bruce L Miller; Kristine Yaffe; Gerard D Schellenberg; Karolina Kauppi; Dominic Holland; Linda K McEvoy; Walter A Kukull; Duygu Tosun; Michael W Weiner; Reisa A Sperling; David A Bennett; Bradley T Hyman; Ole A Andreassen; Anders M Dale; Rahul S Desikan
Journal:  Brain       Date:  2019-02-01       Impact factor: 13.501

2.  Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice.

Authors:  Andrew T Templin; Daniel T Meier; Joshua R Willard; Tami Wolden-Hanson; Kelly Conway; Yin-Guo Lin; Patrick J Gillespie; Krister B Bokvist; Giorgio Attardo; Steven E Kahn; Donalyn Scheuner; Rebecca L Hull
Journal:  Diabetologia       Date:  2018-07-25       Impact factor: 10.122

3.  β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns.

Authors:  Chenyang Jiang; Qingyong Wang; Siwei Xie; Zhicheng Chen; Liping Fu; Qiyu Peng; Ying Liang; Hongbo Guo; Tengfei Guo
Journal:  Brain Commun       Date:  2022-03-31

4.  APOE-ε4 modulates the association among plasma Aβ42/Aβ40, vascular diseases, neurodegeneration and cognitive decline in non-demented elderly adults.

Authors:  Dai Shi; Siwei Xie; Anqi Li; Qingyong Wang; Hongbo Guo; Ying Han; Huaxi Xu; Wen-Biao Gan; Lei Zhang; Tengfei Guo
Journal:  Transl Psychiatry       Date:  2022-03-29       Impact factor: 6.222

5.  Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults.

Authors:  Tengfei Guo; Susan M Landau; William J Jagust
Journal:  Neurology       Date:  2020-03-18       Impact factor: 11.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.